Search Results for 'pfs patients'

pfs patients published presentations and documents on DocSlides.

Btk inhibition in Mantle cell Lymphoma & CLL

Btk inhibition in Mantle cell Lymphoma & CLL

by test

Simon Rule. Professor of Clinical . Haematology. ...

Nouveautés dans le CBNPC métastatique

Nouveautés dans le CBNPC métastatique

by vizettan

Celine Mascaux, MD, . PhD. Multidisciplinary . Onc...

2022 Spring Oncology Conference

2022 Spring Oncology Conference

by byrne

Evolving Treatment Strategies. for CLL/SLL and MCL...

ESMO 2021 (Virtual) Congress Report

ESMO 2021 (Virtual) Congress Report

by SnuggleBug

Lung and gastrointestinal cancers. Slide numbers. ...

Blinded Sample Size Re-estimation in a Phase III Study Investigating Progression Free Survival

Blinded Sample Size Re-estimation in a Phase III Study Investigating Progression Free Survival

by naomi

David Morgan (King’s College, London / Consultan...

YIR On Demand Lung Benjamin Levy, MD

YIR On Demand Lung Benjamin Levy, MD

by jovita

Assistant Professor. Johns Hopkins School of Medic...

Blinded Sample Size Re-estimation in a Phase III Study Inve

Blinded Sample Size Re-estimation in a Phase III Study Inve

by luanne-stotts

David Morgan (King’s College, London / Consulta...

Concomitant administration of palbociclib and proton pump inhibitors affects clinical outcomes in m

Concomitant administration of palbociclib and proton pump inhibitors affects clinical outcomes in m

by felicity

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor...

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Ref

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Ref

by willow

Meletios Dimopoulos,. 1. Hang Quach,. 2. Maria-V...

Summary 2011 Founded 2010

Summary 2011 Founded 2010

by eliza

in Houston. Vision: To be the leader in the develo...

Considerations for Optimizing Transplant in Multiple Myeloma Patient Management

Considerations for Optimizing Transplant in Multiple Myeloma Patient Management

by TravelingSoulmate

PARAMESWARAN HARI MD. MEDICAL COLLEGE OF WISCONSIN...

Managing Advanced Renal Cell

Managing Advanced Renal Cell

by debby-jeon

Carcinoma: Balancing . Efficacy with Quality of L...

BELLE-3: A Phase III Study of

BELLE-3: A Phase III Study of

by faustina-dinatale

Buparlisib. and . Fulvestrant. in Postmenopausa...

Update on Diagnosis and Treatments

Update on Diagnosis and Treatments

by joanne

of Multiple Myeloma. Kenneth C. Anderson, M.D.. J...

Her-2 negative MBC

Her-2 negative MBC

by conchita-marotz

10/25/2016. Objectives. General principles. Endoc...

Update on transplant-ineligible patients:

Update on transplant-ineligible patients:

by trish-goza

Which . regimens are best?. Suzanne Lentzsch MD, ...

iJOURNAL CLUB: Optimizing Therapy for Patients with Metastatic Squamous Cell Carcinoma of the Lung

iJOURNAL CLUB: Optimizing Therapy for Patients with Metastatic Squamous Cell Carcinoma of the Lung

by berey

Interview with Shirish M . Gadgeel. , MD . January...

NEw developments IN gynecological Oncology

NEw developments IN gynecological Oncology

by cheryl-pisano

highlights from the. EUROPEAN . society . of med...

Romidepsin in Association with CHOP in Patients with Peripheral T

Romidepsin in Association with CHOP in Patients with Peripheral T

by accompanypepsi

-Cell . Lymphoma: Final Results of the Phase . Ib....

by billiontins

2018;36(8):773-9.. Nivolumab Monotherapy (Cohort 1...

Colorectal Cancer in Older

Colorectal Cancer in Older

by stingraycartier

Patients. Key Issues. Etienne GC . Brain. , MD . P...

MRD = Minimal Resistant Disease?

MRD = Minimal Resistant Disease?

by shoffer

Roger Owen. St James’s Institute of Oncology. Le...

Advances in Systemic Amyloidosis:

Advances in Systemic Amyloidosis:

by morton

A Spotlight on New Disease-Modifying . Therapies A...

Impact of Imatinib interruption & duration of prior Hydroxyurea on treatment outcome in CML pat

Impact of Imatinib interruption & duration of prior Hydroxyurea on treatment outcome in CML pat

by hadly

Raafat. R. Abdel-. Malek. , MD, FRCR. Ass. Prof C...

GI CONNECT MEETING SUMMARY

GI CONNECT MEETING SUMMARY

by hanah

upper . gi. cancer HIGHLIGHTS . FROM ESMO 2022. D...

Meeting summary ASCO GU 2020,

Meeting summary ASCO GU 2020,

by patricia

San Francisco. , USA. Assoc. . Prof. . Shilpa Gupt...

Treatment escalation in patients with early stage Hodgkin lymphoma and a positive PET scan after in

Treatment escalation in patients with early stage Hodgkin lymphoma and a positive PET scan after in

by fanny

. A subsidiary analysis of the UK NCRI RAPID study...

INTRODUCTION RESULTS

INTRODUCTION RESULTS

by arjun383

Mason Alford, MSc. a. , . Candace J. Grisham, MS. ...

ASCO 2012 Review Gynecologic Cancer

ASCO 2012 Review Gynecologic Cancer

by welnews

Nelson Teng, M.D., Ph.D.. Director, Gynecologic On...

Indolent Non-Hodgkin L

Indolent Non-Hodgkin L

by danika-pritchard

ymphoma. Sobia Ozair. March 8, 2017. MD Anderson ...

Overall Survival Benefit of

Overall Survival Benefit of

by tatyana-admore

Obinutuzumab. Over Rituximab when Combined with ...

by phoebe-click

. Highlights from the Annual Clinical Meeting. G...

17th Annual International Congress

17th Annual International Congress

by conchita-marotz

on . Hematologic Malignancies. ®. : . Focus . on...

by tatiana-dople

Agents . for . Indolent . L. ymphoma . and . Mant...

Impact of Imatinib interruption & duration of prior Hyd

Impact of Imatinib interruption & duration of prior Hyd

by pamella-moone

Raafat. R. Abdel-. Malek. , MD, FRCR. Ass. Prof ...

Department of GI Medical Oncology

Department of GI Medical Oncology

by danika-pritchard

Does . the New EPOC trial . eliminate. . Anti. -...

by cheryl-pisano

Le Chevalier, . MD. The Role of Translational Res...

Immunotherapy for

Immunotherapy for

by sherrill-nordquist

High-Risk and Metastatic Melanoma. Timothy M. Kuz...

Where we are with targeted

Where we are with targeted

by stefany-barnette

therapies . for . cholangiocarcinoma. Professor J...

EGFR-Mutated Advanced NSCLC

EGFR-Mutated Advanced NSCLC

by sherrill-nordquist

The Coming Paradigm Shift. Faculty. Suresh S. Ram...